A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

  • Cancer
  • Breast Cancer
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • Essen
  • Meldola
  • Roma
Trial Identifier:

NCT06274515 WO44977

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This study will evaluate mechanisms of resistance to anti-breast cancer therapies in tumor and blood samples from participants with human epidermal growth factor receptor (HER2) positive, hormone receptor (HR) positive or triple negative breast cancer.

      Hoffmann-La Roche Sponsor
      Phase 4 Phase
      NCT06274515,WO44977 Trial Identifier
      Tumor Tissue and Blood Draw Treatments
      Breast Cancer Condition
      Official Title

      A Multi Cohort Translational Research Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria

      General Inclusion Criteria:

      • Willingness to undergo a procedure to obtain tumor tissue (e.g. biopsy) and blood draw
      • Diagnosis of HER2+, HR+ (for cohort R1) or triple negative breast cancer (for cohort T1) as per local assessment
      • Availability of an archival tumor tissue (most recent pre-treatment tumor tissue is preferred)
      • Unequivocally growing tumor lesion (progressive lesion) that is accessible for resection, excision or core needle biopsy
      • Discontinuation of prior anti-cancer treatment outlined below should not be longer than 4 weeks from participation in this study

      Inclusion criteria for participants in the cohorts studying acquired resistance

      • Participant had undergone regular monitoring for disease progression as per local practice (preferably every 3-6 months) while on most recent breast cancer therapy
      • Accessible tumor lesion that newly appeared or a lesion that started to regrow while the participant was at least 6 months on therapy

      Inclusion criteria for participants in the cohort studying primary resistance

      • Accessible tumor lesion that continued to increase in size or a newly appearing lesion (as confirmed by routine tumor assessment) while treated for at least 4 weeks but less than 6 months on therapy
      Exclusion Criteria
      • Any risks factors that increase the risk of complications associated with the procedure to obtain tumor tissue (e.g. bleeding disorders)
      • Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in and completion of the study
      • Participant has started treatment with subsequent anti-cancer therapy
      • Participants whose progressive tumor lesion that is targeted for biopsy/resection is in the bone
      • Discontinuation of treatment was due to a reason other than disease progression

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now